News
First NanoMedSyn studies to improve Pompe disease treatment published by Angewandte. Angew Chem Int Ed Engl. 2016 DOI: 10.1002/anie.201607824R2
Orphan designation was granted by European commission for the recombinant GAA-AMFA developed by NanoMedSyn for the treatment of Pompe’s disease. EMA (EU/3/16/1726)
Lire l’article complet
Le Grand Prix « Sciences de la Vie » est décerné à NanoMedSyn au Sénat lors de la finale du 16e concours Tremplin Entreprises.
http://www.rare2015.com/index.php
Information reliée par l’Académie des sciences
Published by ECOMNEWS on September 1st, 2015 Publihed by BIOTECHFINANCES on September 4th, 2015 Published by Heraultjuridique.com on September 7th, 2015
Review in Languedoc-Roussillon Magazine, L’accent du Sud, N°38, p9” on Medical Research: “Nanoparticles to fight cancer”.
Increase of capital funding of NanoMedSyn for internal R &D in lysosomal diseases and cancer.